Cargando…

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach

OBJECTIVE: To clarify the oncological benefit of zoledronic acid for hormone-naïve metastatic prostate cancer, patient outcome of androgen deprivation therapy with zoledronic acid (ADT + Z) and androgen deprivation therapy alone (ADT) was compared. METHODS: Fifty-two patients with pathologically con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagao, Kazuhiro, Matsuyama, Hideyasu, Nozawa, Masahiro, Hara, Isao, Nishioka, Tsukasa, Komura, Takahiro, Esa, Atsunobu, Uejima, Shigeya, Imanishi, Masaaki, Uekado, Yasunari, Ogawa, Takatoshi, Kajikawa, Hiroshi, Uemura, Hirotsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Second Military Medical University 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730815/ https://www.ncbi.nlm.nih.gov/pubmed/29264160 http://dx.doi.org/10.1016/j.ajur.2015.10.003

Ejemplares similares

Clinical Outcome of Small Renal Cell Carcinoma after Delayed Surgery versus Immediate Surgery
por: Sugimoto, Koichi, et al.
Publicado: (2013)

Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis
por: Matsumura, Naoki, et al.
Publicado: (2021)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer
por: Miyoshi, Yasuhide, et al.
Publicado: (2021)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery
por: Sugimoto, Koichi, et al.
Publicado: (2013)

Prognosis and safety of radium‐223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration‐resistant prostate cancer: Real‐world data of Japanese patients
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer
por: Nishimoto, Mitsuhisa, et al.
Publicado: (2022)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer
por: Niraula, Saroj, et al.
Publicado: (2017)

Novel bone microenvironment model of castration-resistant prostate cancer with chitosan fiber matrix and osteoblasts
por: Samoto, Masahiro, et al.
Publicado: (2021)

Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study
por: Suzuki, Kazuhiro, et al.
Publicado: (2019)

Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan
por: Matsuyama, Hideyasu, et al.
Publicado: (2023)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer
por: Kazama, Hirotaka, et al.
Publicado: (2022)

Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m(2)) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study
por: Matsuyama, Hideyasu, et al.
Publicado: (2020)

The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer
por: Iwamoto, Genta, et al.
Publicado: (2021)

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
por: Akaza, Hideyuki, et al.
Publicado: (2016)

Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis
por: Watanabe, Daisuke, et al.
Publicado: (2021)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
por: Sakamoto, Shinichi, et al.
Publicado: (2019)

Suppressive Effect and Molecular Mechanism of Houttuynia cordata Thunb. Extract against Prostate Carcinogenesis and Castration-Resistant Prostate Cancer
por: Subhawa, Subhawat, et al.
Publicado: (2021)

Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report
por: Koguchi, Dai, et al.
Publicado: (2021)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide
por: Kawahara, Takashi, et al.
Publicado: (2023)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
por: Kawahara, Takashi, et al.
Publicado: (2020)

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Ureter metastatic castration-resistant prostate cancer: a case report
por: Tsutsumi, Sohgo, et al.
Publicado: (2017)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel
por: Noguchi, Masanori, et al.
Publicado: (2021)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

A Case of Castration for Hypertrophied Prostate
Publicado: (1897)

Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade
por: Nishizawa, Satoshi, et al.
Publicado: (2014)

Treatment strategies and outcomes in a long‐term registry study of patients with high‐risk metastatic hormone‐naïve prostate cancer in Japan: An interim analysis of the J‐ROCK study
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
por: Akoury, Elie, et al.
Publicado: (2019)

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
por: Small, E J, et al.
Publicado: (2019)

Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer
por: Hiroshige, Tasuku, et al.
Publicado: (2018)

The Effects of Castration and Stilboestrol on Prostatic Tumours in Mice
por: Horning, E. S.
Publicado: (1949)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b6r3ubgubvlp9kbcra70ujc9gr